• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

COVID-19 Patients with Obesity Have Lower Inflammatory Biomarkers, Study Finds


Obese patients hospitalized with COVID-19 had lower levels of inflammation biomarkers but outcomes similar to non-obese patients with elevated levels of those biomarkers.

Patients with overweight and obesity who are infected with COVID-19 have lower levels of COVID-19-related inflammatory markers than normal weight patients, according to an abstract presented at the virtual ObesityWeek® 2020 Interactive meeting this week. 

Study authors, led by Claire Le Guen, MD, of Temple University Hospital, in Philadelphia, also found obese, severely obese, and morbidly obese patients are younger and more likely to present for care with respiratory symptoms.

WHO Obesity Class

Normal weight BMI <25

Overweight BMI 25-30

Obese BMI 30-35

Severe obesity BMI 35-40

Morbid obesity BMI >40

Le Guen and colleagues set out with the current understanding of COVID-19 as an acute pulmonary infection that can progress in severity to cytokine storm syndrome as a result of pervasive dysregulated inflammatory response. Patients with obesity seem particularly vulnerable to this response given the hyperinflammatory nature of the disease. The aim of the study was to further describe the inflammatory profile of patients with obesity and to correlate obesity with other characteristics of virus presentation.

Patients were a retrospective cohort with confirmed COVID-19 infection admitted to the Temple Healthcare system between March and May 2020. Patients were stratified by World Health Organization (WHO) obesity classification; presenting symptoms, disease biomarkers, demographics and outcomes were investigated.


  • Age was found to be inversely related to the obesity class (p<.001)
  • Patients with increasing obesity class presented with more initial symptoms of shortness of breath (p<0.013) as well as cough (p<0.027).
  • Initial D-dimer and ferritin lab values were negatively correlated with increasing obesity class (D-dimer, p<.015; ferritin, p<.0001).
  • A normal or near-normal lymphocyte profile was noted in patients with obesity compared to patients without obesity (Lymphocyte %: 16.8, 16.9, 19.7, 19.7, 20.9; p 0.004).
  • There were no significant differences observed in outcomes of intubation rate (p=0.589), ICU admission (p=0.594), or mortality (p=0.331) across BMI classes


The authors state that patients with obesity were younger and more likely to present to the hospital with respiratory symptoms. They also had reduced levels of COVID-19-related markers of systemic inflammation--an unexpected finding given the association of obesity with baseline hyperinflammation.

Moreover, despite the lower level of inflammatory markers, outcomes among patients with obesity for ICU admission and intubation and even for mortality were comparable to those of non=obese patients with more severe inflammatory profiles.

Given that inflammatory biomarkers are used to guide treatment of patients hospitalized with severe COVID-19 infection, the authors point to the need for further investigation of treatment choice and associated outcomes in this population.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
"Obesity is a Medically Approachable Problem" and Other Lessons with Lee Kaplan, MD, PhD
Related Content
© 2024 MJH Life Sciences

All rights reserved.